Glycemic Monitoring in Cystic Fibrosis

Exclusion Criteria

• •CF prediabetes \& CFRD (n=70)
• •1. Age 10-25 years
• •2. Diagnosis of cystic fibrosis (by newborn screen, sweat chloride testing, or genetic testing)
• •3. History of abnormal oral glucose tolerance testing (2h-glucose \>140, fasting plasma glucose \>100,1hr glucose \>200)
• •4. If taking medication that affects glucose metabolism (ex. Insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics), should be on a stable dose over the past 3 months
• •Healthy controls -
• •1. Known diagnosis of diabetes or prediabetes (including type 1, type 2, MODY), abnormal oral glucose tolerance test (OGTT) (ie. fasting plasma glucose ≥100 or 2hr ≥140 mg/dl) or HbA1c ≥ 5.7%
• •2. BMI ≥85th percentile
• •3. Chronic disease that may affect glucose metabolism or use of medications affecting glucose metabolism in the past 3 months (ex. Insulin, insulin sensitizers, glucocorticoids, atypical antipsychotics)
• •4. Presence of type 1 diabetes auto-antibodies in any individuals with a first degree relative with type 1 diabetes (will only include first degree relatives if they have had previous negative auto-antibody screening performed as part of participation in other studies such as the Trial Net studies at the Barbara Davis Center)
• •5. Acute illness (ex. Asthma exacerbation, gastroenteritis, febrile illness)
• •6. Pregnancy
• •CF participants -
• •1. Diagnosis of type 1 diabetes, type 2 diabetes, or MODY
• •2. Varying doses of medication affecting glucose metabolism in the past 3 months
• •3. Pulmonary exacerbation associated with hospitalization, or systemic steroid requirement in the preceding 6 weeks
• •4. Pregnancy